VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported its full year 2025 financial results and provided business updates.
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported its full year 2025 financial results and provided business updates.
Perimeter Solutions could be due for a bounce as the company capitalizes on increasing demand for fire retardant gear and its recent acquisition, according to UBS. The investment bank upgraded the manufacturer of fire safety equipment to buy from neutral. It also raised its price target on shares to $30 from $26, implying roughly 41% upside from Monday's close. Perimeter has struggled this year, l...
Perimeter Solutions could be due for a bounce as the company capitalizes on increasing demand for fire retardant gear and its recent acquisition, according to UBS. The investment bank upgraded the manufacturer of fire safety equipment to buy from neutral. It also raised its price target on shares to $30 from $26, implying roughly 41% upside from Monday's close. Perimeter has struggled this year, losing more than 22%. PRM YTD mountain PRM year to date But, "as conversations in our coverage have shifted from price/cost opportunities to volume risk, we think PRM stock could be an overlooked safe haven," analyst Joshua Spector said in a note to clients. "We see the stock sell off as overdone ... as PRM has continued to execute well and deploy cash into accretive acquisitions." A major driver of the fire safety and specialty products firm's selloff this year was a large variable compensation payment to its executives, according to UBS. But, that shouldn't continue to drive investors away from the stock. "The high water mark for future payments is near ~$28/sh (~30% upside), which we think provides enough upside to interest investors (dilution baked into our $30 PT)," Spector wrote. The analyst added that fire retardant demand is likely to grow in 2026, based on some early signs at the start of the fire season. The company is also poised to grow its services, in addition to increasing its product output due to its recently completed acquisition of Medical Manufacturing Technologies that was valued at nearly $700 million. As a result, UBS raised its EBITDA expectations for Perimeter to 5% and 9% for this year and 2027, respectively. "The business attributes seem favorable with high margins/returns, low capex , ~50% aftermarket," Spector wrote. Wall Street is split on Perimeter Solutions. Of the two analysts covering the stock, one has a hold on shares, while the other has a buy on them. Perimeter stock is down nearly 23% since the beginning of the year. However, shares are...
(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million.
(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million.
(RTTNews) - The Hershey Company (HSY) said, for fiscal 2026, the company continues to project: total company net sales growth in a range of 4% to 5%, organic net sales growth in a range of 2.5% to 3.5%, reported earnings per share growth of 79% to 89%, and adjusted earnings per s
(RTTNews) - The Hershey Company (HSY) said, for fiscal 2026, the company continues to project: total company net sales growth in a range of 4% to 5%, organic net sales growth in a range of 2.5% to 3.5%, reported earnings per share growth of 79% to 89%, and adjusted earnings per s
U.S. President Donald Trump speaks during the Future Investment Initiative (FII) Summit in Miami Beach, Florida, on March 27, 2026. Mandel Ngan | AFP | Getty Images President Donald Trump has warned the U.K. and France that the "U.S.A. won't be there to help you anymore," as he vented his frustration over the close allies' refusal to join military action against Iran. Posting on Truth Social , Tru...
U.S. President Donald Trump speaks during the Future Investment Initiative (FII) Summit in Miami Beach, Florida, on March 27, 2026. Mandel Ngan | AFP | Getty Images President Donald Trump has warned the U.K. and France that the "U.S.A. won't be there to help you anymore," as he vented his frustration over the close allies' refusal to join military action against Iran. Posting on Truth Social , Trump said "the Country of France wouldn't let planes headed to Israel, loaded up with military supplies, fly over French territory." "France has been VERY UNHELPFUL with respect to the "Butcher of Iran," who has been successfully eliminated! The U.S.A. will REMEMBER!!!," he said in a post Tuesday. In another post, the president singled out the U.K. for criticism. "All of those countries that can't get jet fuel because of the Strait of Hormuz, like the United Kingdom, which refused to get involved in the decapitation of Iran, I have a suggestion for you: Number 1, buy from the U.S., we have plenty, and Number 2, build up some delayed courage, go to the Strait, and just TAKE IT," he commented. "You'll have to start learning how to fight for yourself, the U.S.A. won't be there to help you anymore, just like you weren't there for us. Iran has been, essentially, decimated. The hard part is done. Go get your own oil!," he concluded. Trump has expressed his disdain for European allies that have refused to take part in the U.S. and Israel's military operation against Iran, and particularly their reluctance to get involved in what would be highly dangerous efforts to re-open the Strait of Hormuz to interntional shipping. The maritime passage has been almost completely shut by Iran, restricting global oil and gas supplies that are shipped through the strait and a number of tankers have been attacked by Iran during attempts to navigate the Iran-controlled sea route. Trump has criticized NATO allies for not assisting the U.S., telling reporters last week that he thought the military alli...
Contracts tied to US stocks advanced early Tuesday as President Donald Trump indicated he’s willing to end America’s military campaign against Iran even if the Strait of Hormuz remains largely closed. Futures tied to the S&P 500 Index rose 1% as of 7:34 a.m. in New York, while contracts on the Nasdaq 100 Index gained 0.9%. The S&P 500 closed the previous trading session less than 1% away from the ...
Contracts tied to US stocks advanced early Tuesday as President Donald Trump indicated he’s willing to end America’s military campaign against Iran even if the Strait of Hormuz remains largely closed. Futures tied to the S&P 500 Index rose 1% as of 7:34 a.m. in New York, while contracts on the Nasdaq 100 Index gained 0.9%. The S&P 500 closed the previous trading session less than 1% away from the level that places it in a technical correction, or at least 10% from its Jan. 27 peak. Crude prices rose in early trading as Iran hit a fully laden Kuwaiti oil tanker near Dubai in a drone attack. That move may have been capped in part because of a Wall Street Journal report that said Trump is willing to wind down hostilities and apply diplomatic pressure on Tehran instead. Read More: Trump Tells Allies to ‘Go Get’ Jet Fuel From Iran Via Hormuz Despite their climb, equity futures are off of the highs of overnight trading, “highlighting the paralysis created by continually shifting White House” statements, according to Andrew Tyler , head of global market intelligence at JPMorgan Chase & Co. The S&P 500 is on track to close out its worst month since 2022 as conflict in the Middle East has roiled financial markets and sent oil surging. US gasoline prices rose above $4 gallon for the first time since 2022. Energy goods and services accounted for just 3.7% of consumer spending in January compared to 5.6% before Iraq invaded Kuwait in 1990, according to data from Bank of America Corp., providing some solace that the economy “has become much more energy-efficient over time, making it more resilient to energy shocks,” BofA economist Aditya Bhave wrote in a client note. In individual movers, Whoop Inc. , the maker of popular screenless fitness bands, reached a $10.1 billion valuation, a new milestone on its way to an initial public offering. Unilever Plc said talks to sell most of its food business to McCormick & Co. are advanced and a final deal could be announced later on Tuesday...
In this article NVO NVO HIMS LLY Follow your favorite stocks CREATE FREE ACCOUNT Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, "predictable" monthly prices. Eligible patients can choose between three-, six- ...
In this article NVO NVO HIMS LLY Follow your favorite stocks CREATE FREE ACCOUNT Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, "predictable" monthly prices. Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name. Longer plans offer lower monthly pricing, and the company expects people to save up to $1,200 a year on the injection and as much as $600 a year on the pill, relative to paying for their individual dose each month, according to a Novo release. Patients can expect to pay flat monthly prices, even if they move to different doses, the company said. The subscription program will be available starting Tuesday on several of Novo's telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame and Hims & Hers , with more expected to be added soon. The first-of-its-kind offering is "an opportunity to help patients not only start but stay on therapy and help them manage the ups and downs of some of the pricing considerations," regardless if they are starting treatment or are currently taking the drug, said Ed Cinca, Novo's head of marketing and patient solutions. Inability to stay on GLP-1s is a longstanding issue due to factors such as difficulty accessing the drugs and gastrointestinal side effects, with one 2025 study estimating that around 65% of patients with obesity stop treatment within a year. Wegovy subscription prices and estimated savings Injection subscription plans (0.25, 0.5, 1.7 and 2.4 milligram doses) 3-month: $329 per month, savings of $240 per year 6-month: $299 per month, savings of $600 per year 12-month: $249 per month, savings of $1,200 per year Pill subscription plans (9 and 25 milligram doses) 3-month: $289 per month, savings o...